RAS Mutations Are Not Created Equal.

abstract：:Cancer cells must rewire cellular metabolism to satisfy the demands of growth and proliferation. Although many of the metabolic alterations are largely similar to those in normal proliferating cells, they are aberrantly driven in cancer by a combination of genetic lesions and nongenetic factors such as the tumor micro...

journal_title：Cancer discovery

authors： Cantor JR,Sabatini DM

更新日期：2012-10-01 00:00:00

abstract：:Margetuximab outperformed trastuzumab in a phase III, head-to-head trial of the two anti-HER2 agents among patients with HER2-positive metastatic breast cancer. The new antibody drug was engineered for enhanced immune activity against HER2-expressing tumor cells. ...

journal_title：Cancer discovery

authors：

更新日期：2019-08-01 00:00:00

abstract：:A recent study suggests that natural killer (NK) cells may play an important role in antitumor response to immune checkpoint inhibitors. Researchers used mouse models to show that NK cells respond to PD-1 and PD-L1 inhibitors, information that could be used to develop immunotherapies that tap NK cells to combat cancer...

journal_title：Cancer discovery

authors：

更新日期：2018-12-01 00:00:00

abstract：:Genetic alterations in the fibroblast growth factor receptor (FGFR) pathway are promising therapeutic targets in many cancers, including intrahepatic cholangiocarcinoma (ICC). The FGFR inhibitor BGJ398 displayed encouraging efficacy in patients with FGFR2 fusion-positive ICC in a phase II trial, but the durability of ...

journal_title：Cancer discovery

authors： Goyal L,Saha SK,Liu LY,Siravegna G,Leshchiner I,Ahronian LG,Lennerz JK,Vu P,Deshpande V,Kambadakone A,Mussolin B,Reyes S,Henderson L,Sun JE,Van Seventer EE,Gurski JM Jr,Baltschukat S,Schacher-Engstler B,Barys L,Stam

更新日期：2017-03-01 00:00:00

abstract：:Primary and acquired resistance to anti-epidermal growth factor receptor (EGFR) drugs are clinically relevant problems in patients with metastatic colorectal carcinoma. A complex network of molecular alterations is involved in this phenomenon. Bertotti et al. report the development of serially transplantable groups of...

journal_title：Cancer discovery

authors： Ciardiello F,Normanno N

更新日期：2011-11-01 00:00:00

abstract：:Circadian rhythms integrate many physiological pathways, helping organisms to align the timing of various internal processes to daily cycles in the external environment. Disrupted circadian rhythmicity is a prominent feature of modern society, and has been designated as a probable carcinogen. Here, we review multiple ...

journal_title：Cancer discovery

authors： Pariollaud M,Lamia KA

更新日期：2020-10-01 00:00:00

abstract：: BRAF fusions and mutations are the most frequent genetic alterations in pediatric low-grade gliomas. The work from Wang and colleagues identifies an acquired secondary BRAF mutation that confers resistance to pharmacologic BRAF inhibition in a BRAFV600E glioma. The authors demonstrate that the mu...

journal_title：Cancer discovery

authors： Romano G,Kwong LN

更新日期：2018-09-01 00:00:00

abstract：:HDAC inhibitors synergize with PI3K inhibitors to reduce MYC-driven medulloblastoma (MB) growth. ...

journal_title：Cancer discovery

authors：

更新日期：2016-05-01 00:00:00

abstract：:Although comprehensive genomic screening has not yet become routine when treating patients with cancer, widespread testing in those with advanced, refractory disease is feasible, according to the ongoing ProfiLER study. The study also found that patients who subsequently received a treatment matched to the genetic cha...

journal_title：Cancer discovery

authors：

更新日期：2017-08-01 00:00:00

abstract：:A report from the National Academies of Sciences, Engineering, and Medicine lays out 12 recommendations to help scientists decide whether to return research results to study participants and, if they do, how to improve the sharing of information. The most important change the report recommends is harmonizing contradic...

journal_title：Cancer discovery

authors：

更新日期：2018-09-01 00:00:00

abstract：:AKT inhibitors have promising activity in AKT1E17K-mutant estrogen receptor (ER)-positive metastatic breast cancer, but the natural history of this rare genomic subtype remains unknown. Utilizing AACR Project GENIE, an international clinicogenomic data-sharing consortium, we conducted a comparative analysis of clinica...

journal_title：Cancer discovery

authors： Smyth LM,Zhou Q,Nguyen B,Yu C,Lepisto EM,Arnedos M,Hasset MJ,Lenoue-Newton ML,Blauvelt N,Dogan S,Micheel CM,Wathoo C,Horlings H,Hudecek J,Gross BE,Kundra R,Sweeney SM,Gao J,Schultz N,Zarski A,Gardos SM,Lee J,S

更新日期：2020-04-01 00:00:00

abstract：:Adding a PI3K inhibitor to anti-estrogen receptor therapy may be a viable treatment option for women with advanced hormone receptor-positive breast cancer that becomes resistant to endocrine therapy, according to findings from the phase III BELLE-2 trial, presented at the 2015 San Antonio Breast Cancer Symposium. ...

journal_title：Cancer discovery

authors：

更新日期：2016-02-01 00:00:00

abstract：:CDK4/6 inhibition with endocrine therapy is now a standard of care for advanced estrogen receptor-positive breast cancer. Mechanisms of CDK4/6 inhibitor resistance have been described preclinically, with limited evidence from clinical samples. We conducted paired baseline and end-of-treatment circulating tumor DNA seq...

journal_title：Cancer discovery

authors： O'Leary B,Cutts RJ,Liu Y,Hrebien S,Huang X,Fenwick K,André F,Loibl S,Loi S,Garcia-Murillas I,Cristofanilli M,Huang Bartlett C,Turner NC

更新日期：2018-11-01 00:00:00

abstract：:The NCI and Department of Veterans Affairs (VA) are collaborating on the NCI and VA Interagency Group to Accelerate Trials Enrollment, or NAVIGATE, which will launch at 12 VA facilities across the country. The program aims to increase participation of veterans with cancer in NCI-sponsored clinical trials. ...

journal_title：Cancer discovery

authors：

更新日期：2018-08-01 00:00:00

abstract：:The FDA authorized 23andMe to market the first direct-to-consumer test to check for three BRCA1/2 mutations associated with a higher risk of developing breast, ovarian, and prostate cancers. The mutations are most commonly found in about 2% of women of Ashkenazi Jewish descent. ...

journal_title：Cancer discovery

authors：

更新日期：2018-05-01 00:00:00

abstract：UNLABELLED:Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer that most commonly evolves from preexisting prostate adenocarcinoma (PCA). Using Next Generation RNA-sequencing and oligonucleotide arrays, we profiled 7 NEPC, 30 PCA, and 5 benign prostate tissue (BEN), and validated findings ...

journal_title：Cancer discovery

authors： Beltran H,Rickman DS,Park K,Chae SS,Sboner A,MacDonald TY,Wang Y,Sheikh KL,Terry S,Tagawa ST,Dhir R,Nelson JB,de la Taille A,Allory Y,Gerstein MB,Perner S,Pienta KJ,Chinnaiyan AM,Wang Y,Collins CC,Gleave ME,Demi

更新日期：2011-11-01 00:00:00

abstract：:According to results from ENZAMET, a global phase III trial, adding enzalutamide to standard treatment for men with metastatic hormone-sensitive prostate cancer is superior in prolonging survival compared with older nonsteroidal antiandrogen drugs. ...

journal_title：Cancer discovery

authors：

更新日期：2019-08-01 00:00:00

abstract：:Results from a phase III trial indicate that maintenance therapy with the PARP inhibitor niraparib is more effective than placebo in slowing the progression of recurrent platinum-sensitive ovarian cancer. Improved progression-free survival was seen regardless of the presence or absence of germline BRCA mutations, or o...

journal_title：Cancer discovery

authors：

更新日期：2016-12-01 00:00:00

abstract：:In a phase Ib trial, a combination of the experimental immunotherapy AM0010, a PEGylated form of the recombinant human cytokine IL10, and the anti-PD-1 checkpoint inhibitor pembrolizumab was well tolerated and effective at controlling tumors in some patients with advanced renal cell carcinoma, non-small cell lung canc...

journal_title：Cancer discovery

authors：

更新日期：2016-12-01 00:00:00

abstract：:According to findings of a study in the Journal of the National Cancer Institute, people with a single-nucleotide polymorphism on chromosome 8q24 who regularly use aspirin can cut their risk of colorectal cancer by about half. ...

journal_title：Cancer discovery

authors：

更新日期：2014-03-01 00:00:00

abstract：:A study shows that analyzing the protein contents of exosomes and related extracellular vesicles can distinguish tumors from nearby noncancerous tissue, and profiling extracellular vesicle proteins obtained from plasma may also reveal cancer type. The results support using vesicle proteins for liquid biopsies. ...

journal_title：Cancer discovery

authors：

更新日期：2020-11-01 00:00:00

abstract：:In the plasmaMATCH trial, researchers performed circulating tumor DNA testing on patients with advanced breast cancer and matched those with ESR1, HER2, or AKT1 alterations to targeted therapies. Patients with HER2 and AKT1 mutations experienced response rates greater than 22% with durable benefit. ...

journal_title：Cancer discovery

authors：

更新日期：2020-05-01 00:00:00

abstract：:Recent findings from a phase II trial suggest that combining the antiandrogen abiraterone and the PARP inhibitor olaparib significantly improves progression-free survival among patients with metastatic castration-resistant prostate cancer, regardless of their homologous recombination repair-mutation status. ...

journal_title：Cancer discovery

authors：

更新日期：2018-08-01 00:00:00

abstract：:The California Institute of Quantitative Biosciences offers incubators and other programs that aim to close the gap between discovery and commercialization in biotechnology. ...

journal_title：Cancer discovery

authors：

更新日期：2012-12-01 00:00:00

abstract：:Whether metastases were seeded mono- or polyclonally depended on cancer site and treatment. ...

journal_title：Cancer discovery

authors：

更新日期：2020-07-01 00:00:00

abstract：:A phase II study indicates that sacituzumab govitecan (IMMU-132), a Trop-2-specific antibody linked to the irinotecan metabolite SN-38, prolongs the progression-free survival of patients with advanced triple-negative breast cancer. IMMU-132 is well tolerated, causing fewer and more manageable side effects than irinote...

journal_title：Cancer discovery

authors：

更新日期：2016-01-01 00:00:00

abstract：:To study mechanisms underlying resistance to the BCL2 inhibitor venetoclax in acute myeloid leukemia (AML), we used a genome-wide CRISPR/Cas9 screen to identify gene knockouts resulting in drug resistance. We validated TP53, BAX, and PMAIP1 as genes whose inactivation results in venetoclax resistance in AML cell lines...

journal_title：Cancer discovery

authors： Nechiporuk T,Kurtz SE,Nikolova O,Liu T,Jones CL,D'Alessandro A,Culp-Hill R,d'Almeida A,Joshi SK,Rosenberg M,Tognon CE,Danilov AV,Druker BJ,Chang BH,McWeeney SK,Tyner JW

更新日期：2019-07-01 00:00:00

abstract：:Although BRAF-MEK inhibition can enhance the immune recognition of melanoma cells, the mechanisms that underlie this remain poorly defined. In this issue of Cancer Discovery, Erkes and colleagues present new data showing that BRAF-MEK inhibition activates pyroptosis in melanoma cells through gasdermin E cleavage, lead...

journal_title：Cancer discovery

authors： Smalley KSM

更新日期：2020-02-01 00:00:00

abstract：:BRAF inhibitors stabilize a closed, rigid RAF kinase conformation that facilitates dimerization. ...

journal_title：Cancer discovery

authors：

更新日期：2013-07-01 00:00:00

abstract：:Treating human breast cancer xenografts in mice with bevacizumab or sunitinib has increased the population of cancer stem cells found in the tumors. ...

journal_title：Cancer discovery

authors：

更新日期：2012-03-01 00:00:00